We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+55.06%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.8B
AUM Growth
+$694M
Cap. Flow
+$99M
Cap. Flow %
3.54%
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5
Avg Time Held
2.9 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$63.5M
2
IMNM icon
Immunome
IMNM
+$32.3M
3
BHVN icon
Biohaven
BHVN
+$28.8M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
5
ABT icon
Abbott
ABT
+$26.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$30M
2
HUM icon
Humana
HUM
+$29.1M
3
ELV icon
Elevance Health
ELV
+$28.8M
4
FOLD icon
Amicus Therapeutics
FOLD
+$24M
5
DXCM icon
DexCom
DXCM
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.15%
2 Industrials 3.43%
3 Miscellaneous 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALLK icon
51
DELISTED
Allakos
ALLK
$10M 0.36%
3,670,447
-464,614
-11% -$1.05M
2018 Q3
21 quarters
ACIU icon
52
AC Immune
ACIU
$244M
$10M 0.36%
+2,000,000
New +$6.43M
2023 Q4
0 quarters
RAPT icon
53
DELISTED
RAPT Therapeutics
RAPT
$9.11M 0.33%
45,847
-7,589
-14% -$939K
2022 Q1
7 quarters
STXS icon
54
Stereotaxis
STXS
$105M
$5.95M 0.21%
3,402,443
-2,363,349
-41% -$3.82M
2019 Q3
17 quarters
IVVD icon
55
Invivyd
IVVD
$197M
$5.68M 0.2%
1,440,725
– –
2021 Q3
9 quarters
SNCE
56
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$5.29M 0.19%
990,412
– –
2021 Q4
8 quarters
ATRA icon
57
Atara Biotherapeutics
ATRA
$96.9M
$4.67M 0.17%
364,258
+113,025
+45% +$2.64M
2014 Q4
36 quarters
NUVB icon
58
Nuvation Bio
NUVB
$1.67B
$4.58M 0.16%
3,031,009
– –
2021 Q1
11 quarters
LVTX icon
59
DELISTED
LAVA Therapeutics
LVTX
$3.28M 0.12%
2,074,372
– –
2021 Q1
11 quarters
MDVL
60
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$3.05M 0.11%
692,082
– –
2020 Q4
12 quarters
XERS icon
61
Xeris Biopharma Holdings
XERS
$1.84B
$2.46M 0.09%
1,046,587
– –
2018 Q2
22 quarters
ACHL
62
DELISTED
Achilles Therapeutics
ACHL
$1.43M 0.05%
1,608,089
– –
2021 Q1
11 quarters
KLRS icon
63
Kalaris Therapeutics
KLRS
$52.1M
$1.3M 0.05%
82,955
– –
2020 Q3
13 quarters
SLGC
64
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$938K 0.03%
370,839
-28,600
-7% -$66.6K
2021 Q3
9 quarters
NVTA
65
DELISTED
Invitae Corporation
NVTA
$924K 0.03%
1,474,026
-806,377
-35% -$482K
2020 Q2
14 quarters
HOOK icon
66
DELISTED
HOOKIPA Pharma
HOOK
$862K 0.03%
106,377
– –
2019 Q2
18 quarters
TKNO icon
67
Alpha Teknova
TKNO
$408M
$601K 0.02%
161,005
-123,559
-43% -$305K
2021 Q2
10 quarters
ADAP
68
DELISTED
Adaptimmune Therapeutics
ADAP
$567K 0.02%
715,607
– –
2023 Q2
2 quarters
VTYX icon
69
DELISTED
Ventyx Biosciences
VTYX
$512K 0.02%
207,203
-722,697
-78% -$6.86M
2022 Q3
5 quarters
BCEL
70
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$58.4K ﹤0.01%
442,653
– –
2019 Q2
18 quarters
DXCM icon
71
DexCom
DXCM
$33.1B
– –
-244,391
Closed -$22.8M –
HUM icon
72
Humana
HUM
$51.9B
– –
-59,851
Closed -$29.1M –
XENE icon
73
Xenon Pharmaceuticals
XENE
$3.32B
– –
-419,568
Closed -$14.3M –
CUTR icon
74
DELISTED
Cutera, Inc.
CUTR
– –
-334,996
Closed -$2.02M –
SONX
75
DELISTED
Sonendo, Inc.
SONX
– –
-410,393
Closed -$306K –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2023 Portfolio in Review

As of Q4 2023, Redmile Group held 75 positions worth $2.8B, up 33% from $2.1B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Redmile Group deployed $99M of net new capital in Q4 2023, opening 7 new positions and adding to 22 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Krystal Biotech, an estimated $30M trimmed.

  • Redmile Group's largest Q4 2023 buy was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.
  • Redmile Group added most to Biohaven in Q4 2023, an estimated $28.8M increase.
  • Redmile Group's biggest Q4 2023 reduction was Krystal Biotech, cutting an estimated $30M.
  • Redmile Group fully exited Humana in Q4 2023, selling an estimated $29.1M.
  • Redmile Group's ten largest holdings make up 54% of its $2.8B portfolio in Q4 2023.
  • Redmile Group opened 7 new positions and closed 5 in Q4 2023.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $2.8B.

Based on Redmile Group's 13F filing for Q4 2023, filed 14 Feb 2024.